""

about | Maps & Directions | contact | admissions | faculty | alumni & development | library | Tech Support Center | dean's office | Policies & Procedures

FAculty directory

Back to alphabetical index Kwang Chul Kim, PhD

 

Kwang Chul Kim, PhD

 

Professor, Physiology

Telephone:  215-707-9084

Email: kckim@temple.edu

 

 

Department of Physiology

Center for Inflammation, Translational and Clinical Lung Research

 

Educational Background:

 

BS (Pharmacy), Seoul National University, Seoul, Korea, 1972

 

MS (Medicine), Seoul National University, Seoul, Korea, 1974

 

PhD (Pharmacology), Ohio State University, Columbus, OH, 1979

Return to top

 

 

PROFESSIONAL AFFILIATIONS:

 

  • American Society of Cell Biology
  • American Physiological Society
  • American Society for Biochemistry and Molecular Biology
  • American Thoracic Society
  • Society of Leukocyte Biology
  • Korean Academy of Tuberculosis and Respiratory Diseases

Return to top

 

 

Research Interests:

 

Mucus lining the airway lumen serves as a major protective barrier for the lung. Various airborne particles and toxic chemicals (e.g., bacteria, viruses, pollens, various toxicants, etc.) are trapped in this mucus layer and continuously cleared by a process called mucociliary clearance. Therefore, any abnormalities in the quality and quantity of mucus can cause serious pulmonary complications often leading to the death of patients as can be seen in pulmonary diseases such as cystic fibrosis, chronic bronchitis, bronchiectasis and asthma. Mucins are the major glycoproteins present in the mucus, which determine its physicochemical properties of the mucus. They are produced by underlying epithelial cells. Excessive production of mucins is responsible for airway obstruction and infection. We have identified an agent that can suppress airway mucin hypersecretion in an animal model, which has received a U.S. patent.

 

In 1987, we published an interesting observation that some mucins are present on the apical surface of airway goblet cells and releasable by neutrophil elastase. Later, they were identified as MUC1 mucins (MUC for human, Muc for animals) which were originally discovered in breast cancer cells and have been shown to play crucial roles during metastasis. In the lung, however, MUC1/Muc1 is an adhesion site for Pseudomonas aeruginosa, a bacterium that is invariably associated with the airway of cystic fibrosis patients. The adhesion of Pseudomonas to the ectodomain of MUC1/Muc1 resulted in tyrosine phosphorylation of its cytoplasmic tail and activation of a MAP kinase. Using Muc1 knockout mice, we have also shown that Muc1 is an anti-inflammatory molecule during respiratory infection, and its anti-inflammatory activity is mediated through interaction of its cytoplasmic tail with Toll-like receptors (TLRs). We hypothesize that MUC1/Muc1 plays an important role in the genesis of chronic inflammatory lung diseases. With our recent U.S. patent, a translational research is currently under way, in collaboration with a number of laboratories within as well as outside the U.S., to develop drugs to control chronic respiratory inflammation as in chronic obstructive pulmonary disease (COPD) and cystic fibrosis.

 

Our current research interests are:


(1) To further elucidate the molecular interaction between MUC1 and TLRs in the presence of EGFR (Kato K. et al, J Immunol 188:2014, 2012).
(2) To understand the role of MUC1 in other cell types in the lung, including type II pneumocytes and alveolar macrophages (Yen JH et al, Brain Behav Immun 29:70, 2013.
(3) To determine whether MUC1/Muc1 is involved in the genesis of COPD (Umehara T. et al, Inflamm Res 61:1013, 2012).


Return to top

 

 

 

Selected PUBLICATIONS:

 

Kim KC, Lillehoj EP (2008) MUC1 mucin: a peacemaker in the lung. Am J Respir Cell Mol Biol 39:644-647.

 

Return to top